Novartis: asthma inhaler meets clinical trial goal

(CercleFinance.com) - Swiss drugmaker Novartis said on Friday that its new inhaled dual combination against asthma has met its primary endpoint in a late-stage trial.


Data from a 52-week pivotal Phase III clinical trial demonstrated that QMF149, a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate, was superior to mometasone furoate in improving lung function.

Statistically significant superiority compared to mometasone furoate alone was also demonstrated in the key secondary endpoint of improvement in asthma control, Novartis said.

Copyright (c) 2019 CercleFinance.com. All rights reserved.